https://prabadinews.com/
FDA Approves Pegcetacoplan to Reduce Proteinuria in 2 Kidney-Related Diseases

The treatment proved efficacy across all 3 key markers of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).

administrator

Related Articles